Encapsulated cell therapy - IsoTis OrthoBiologics

Drug Profile

Encapsulated cell therapy - IsoTis OrthoBiologics

Alternative Names: ECT - IsoTis OrthoBiologics

Latest Information Update: 13 Dec 2016

Price : $50

At a glance

  • Originator StemCells
  • Developer IsoTis OrthoBiologics; Novartis
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anaemia; Solid tumours

Most Recent Events

  • 28 Nov 2016 StemCells has been acquired by Microbot Medical
  • 09 Nov 2005 No development reported - Phase-I for Anaemia in Switzerland (unspecified route)
  • 09 Nov 2005 No development reported - Preclinical for Solid tumours in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top